65 a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rhfgf18 Administered Intraarticularly Using Single or Multiple Ascending Doses in Patients WFTH Primary Knee Osteoarthritis (Oa), Not Expected to Require Knee Surgery Within 1 Year

McPherson, Ruth; Flechsenhar, K.; Hellot, Scarlett; Eckstein, Friedrich S.

doi:10.1016/s1063-4584(11)60092-7

Cited by 8 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One relevant example of PHC in OA may be found in the recent fibroblast growth factor (FGF)-18 studies. In a retrospective analysis of data from a clinical trial with Sprifermin (rhFGF18) 67 , a combination of two SNPs in the IL1RN gene could be indicative of disease severity/progression as well as potential response to Sprifermin in defined genetic groups 68 . Four groups of patients were identified and tested for a statistical association with change in cartilage thickness/volume (as measured by MRI) and WOMAC scores.…”

Section: Do Different Phenotypes In Oa Represent Different Pathologicmentioning

confidence: 99%

Osteoarthritis – a case for personalized health care?

Karsdal

Christiansen

Ladel

et al. 2014

Osteoarthritis and Cartilage

135

115

View full text Add to dashboard Cite

For both economic and ethical reasons, identification of the optimal treatment for each individual patient is a pressing concern, not only for the patients and their physician, but also health care payers and the pharmaceutical industry. In the field of osteoarthritis (OA) this is of particular relevance, due to the heterogeneity of the disease and the very large number of affected individuals. There is a need to pair the right patients with the right therapeutic modes of action. At present, the clinical trial failures in OA may be a consequence of both bona fide treatment failures and trial failures due to clinical design deficiencies. Tools are needed for characterization and segregation of patients with OA. Key lessons may be learned from advances with another form of arthritis, namely rheumatoid arthritis (RA). Personalized health care (PHC) may be more advantageous for a number of specific indications which are characterized by costly therapy, low response rates and significant problems associated with trial and error prescription, including the risk of serious side effects. We discuss the use of diagnostic practices guiding RA treatment, which may serve as a source of key insights for diagnostic practices in OA. We discuss the emerging concept of PHC, and outline the opportunities and current successes and failures across the RA field, as the OA field collects further data to support the hypothesis. We attempt to outline a possible path forward to assist patients, physicians, payers and the pharmaceutical industry in assuring the 'right' patients are treated with the 'right drug' in OA. Finally we highlight methods for possible segregation of OA patients that would allow identification of patient subtypes, such as OA driven by inflammation that may be ideally suited for PHC and for targeted therapies.

show abstract

Section: Do Different Phenotypes In Oa Represent Different Pathologicmentioning

confidence: 99%

Osteoarthritis – a case for personalized health care?

Karsdal

Christiansen

Ladel

et al. 2014

Osteoarthritis and Cartilage

135

115

View full text Add to dashboard Cite

show abstract

“…Results showed a statistically significant dose-dependent improvement in total femoro tibial cartilage volume (P <0.05), as well as diminished JSN at 1 year post injection. 22 All 42 patients receiving rhFGF18 experienced symptomatic improvement, although the response in the placebo group was higher than with active treatment. This early result shows that rhFGF18 has potential DMOAD activity but that further clinical investigation is clearly needed.…”

Section: Bone Morphogenetic Proteinmentioning

confidence: 94%

Functional articular cartilage repair: here, near, or is the best approach not yet clear?

2013

View full text Add to dashboard Cite

In this Review we describe three approaches for cartilage tissue repair at the rheumatology-orthopaedics interface: disease-modifying osteoarthritis (OA) drug (DMOAD) treatment; cell-based therapies, and intrinsic cartilage repair by joint distraction. DMOADs can slow the progression of joint damage. Cell-based therapies have evolved to do the same, through selection of the most potent cell types (and combinations thereof), as well as identification of permissive boundary conditions for indications. Joint distraction techniques, meanwhile, have now demonstrated the capacity to stimulate actual intrinsic tissue repair. Although this progress is promising, true biological joint reconstruction remains distant on the developmental pathway of 'regenerative medicine'. Prolonged functional repair--that is, cure of diseases such as OA--remains an unmet medical need and scientific challenge, for which comparative and constructive interaction between these physical, chemical and cellular approaches will be required. Careful selections of patients and combinations of approaches will need to be made and tested to demonstrate their cost-effectiveness. Only with such rational and integrated assessment of outcomes will the promising results of these approaches be consolidated in clinical practice.

show abstract

Pathophysiology of Temporomandibular Disorders

Stegenga

2019

Contemporary Management of Temporomandibular Disorders

View full text Add to dashboard Cite

65 a Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rhfgf18 Administered Intraarticularly Using Single or Multiple Ascending Doses in Patients WFTH Primary Knee Osteoarthritis (Oa), Not Expected to Require Knee Surgery Within 1 Year

Cited by 8 publications

References 0 publications

Osteoarthritis – a case for personalized health care?

Osteoarthritis – a case for personalized health care?

Functional articular cartilage repair: here, near, or is the best approach not yet clear?

Pathophysiology of Temporomandibular Disorders

Contact Info

Product

Resources

About